Risk factors for severity of colonic diverticular hemorrhage

Ken Kinjo1, Toshiyuki Matsu1, Takashi Hisabe1, Hiroshi Ishihara1, Toshiki Kojima2, Kenta Chuman2, Shigeyoshi Yasukawa1, Tsuyoshi Beppu1, Akihiro Koga1, Satoshi Ishikawa1, Masahiro Kishi1, Noritaka Takatsu1, Fumihito Hira1, Kenshi Yao2, Toshiharu Ueki1, Masakazu Washio3

Departments of 1Gastroenterology and 2Endoscopy, Fukuoka University Chikushi Hospital, Chikushino, 3Department of Community Health and Clinical Epidemiology, St. Mary’s College, Kurume, Japan

Background/Aims: Colonic diverticular hemorrhage (DH) was a rare disease until the 1990s, and its incidence has increased rapidly since 2000 in Japan. In recent years, colonic DH has been the most frequent cause of lower gastrointestinal bleeding (LGIB). Nearly all cases of DH are mild, with the bleeding often stopping spontaneously. Some cases, however, require surgery or arterial embolization. In this study, using a cohort at Fukuoka University Chikushi Hospital, we investigated factors associated with severe colonic DH. Methods: Among patients with LGIB who underwent colonoscopy at our hospital between 1995 and 2013, DH was identified in 273 patients. Among them, 62 patients (22.7%) were defined as having severe colonic DH according to recurrence of bleeding in a short period, and/or the necessity of transfusion, arterial embolization, or surgery. We then evaluated risk factors for severe DH among DH patients in this retrospective cohort. Results: Among the 273 patients with DH, use of non-steroidal anti-inflammatory drugs (NSAIDs) (odds ratio [OR], 2.801; 95% confidence interval [CI], 1.164–6.742), Charlson Risk Index (CRI) ≥2 (OR, 3.336; 95% CI, 1.154–7.353), right-sided colonic DH (OR, 3.873; 95% CI, 1.554–9.653), and symptoms of cerebral hypoperfusion (such as light-headedness, dizziness, or syncope) (OR, 2.926; 95% CI, 1.310–6.535) showed an increased risk of severe DH even after controlling for other factors. Conclusions: Severe DH occurred in 23% of DH patients, and NSAID use, CRI ≥2, right-sided colonic DH, and symptoms of cerebral hypoperfusion are suggested to be predictors of severe DH. (Intest Res 2018;16:458-466)

Key Words: Colonic diverticular hemorrhage; Severity risk factors; Anti-inflammatory agents, non-steroidal; Right-sided colonic diverticular hemorrhage

INTRODUCTION

The use of oral antithrombotic drugs (ATDs) and NSAIDs is increasing with the aging of the population. The number of patients with conditions causing lower gastrointestinal bleeding (LGIB) is also increasing in developed countries, including Japan.1-4 In particular, the prevalence of colonic diverticulum is increasing in Japan. Around 75% to 80% of patients with colonic diverticula remain asymptomatic throughout life.5 A small number of these patients develop complications such as diverticulitis or diverticular perforation, but the most common complication is diverticular hemorrhage (DH).6 DH is also increasing in Japan, accounting for 28% to 47% of LGIB cases since 2000, and is now one of the most common causes of LGIB.1,6

We previously reported risk factors for DH in patients with diverticulosis.1 However, we did not evaluate risk factors for severe DH among these patients. The present study aims to identify factors associated with severity of DH among colonic DH patients.
METHODS

1. Patients and Subjects

Between January 1995 and December 2013, a total of 42,540 patients underwent colonoscopy (CS) at Fukuoka University Chikushi Hospital, one of the main emergency hospitals in Chikushino City, Fukuoka, Japan. The present retrospective study included all patients who underwent CS for overt LGIB during this 19-year period. As reported previously, 273 patients (172 men and 101 women) received a diagnosis of DH (207 confirmed colonic DH and 66 suspected colonic DH). They were 69.0±13.3 years old at diagnosis. In this study, severe DH was defined as the need for blood transfusion (transfusion of ≥2 units of packed red blood cells), rebleeding during hospitalization, the need for vascular embolization or surgical treatment after endoscopic hemostasis, or death. As such, 62 patients were classified as having severe DH, while the remaining 211 patients were classified as non-severe DH. We thus investigated 62 cases of severe DH and 211 cases of non-severe DH to evaluate risk factors for severe DH among DH patients in this nested case-control study, using the data-set of our retrospective cohort.

Factors evaluated included sex (male/female), age ≥70 years, and BMI. BMI was calculated as weight divided by the square of height (kg/m²). Patients were categorized into 3 groups according to the use of oral ATDs (266 low-dose aspirin or other drugs mentioned in the previous report, 58 anticoagulants warfarin and dabigatran): no ATDs; 1 oral ATD; or ≥2 oral ATDs. Use of NSAIDs (drugs mentioned in the previous report) was also examined.

Two-group comparisons for lifestyle factors included smoking and alcohol use. We regarded current and previous smoking as representing a positive history of smoking, while only current drinking was defined as positive for alcohol. Other factors examined included history of laparotomy and other background pathology (cerebrovascular disease, ischemic heart disease, hypertension, hyperlipidemia, hyperuricemia, diabetes mellitus, chronic liver disease, and chronic kidney disease). Comorbidity was quantified using the Charlson Risk Index (CRI). Two groups were compared: CRI ≤1 and CRI ≥2.

The anatomic distribution of colonic diverticula was divided into 3 groups for comparison: right-sided DH with bleeding from a diverticulum in the cecum, ascending colon, or transverse colon; left-sided DH with bleeding from a diverticulum in the descending or sigmoid colon; and source of bleeding unknown.

The presence or absence of associated symptoms was also compared, with associated symptoms defined as any of the following: abdominal pain, diarrhea, or symptoms of cerebral hypoperfusion (light-headedness or dizziness or syncope).

This study was approved by the Institutional Review Board of Fukuoka University Chikushi Hospital (IRB No. R15-024) and was conducted in accordance with the Declaration of Helsinki. Since this was a retrospective study, the need to obtain informed consent to participate in the study was waived by the review board.

2. Diagnosis

CS was generally performed on the day of overt bleeding or the day thereafter. Depending on the clinical symptoms and physical examination findings in each patient, CS was performed without pretreatment, or after pretreatment with an enema or bowel-cleansing agent. Olympus colonoscopes (PCF-240AZI, PCF-240AI, CF-240AZI, CF-240ZI, PCF-260AZI, PCF-PQ260I, and CF-260AI; Olympus, Tokyo, Japan) were used for all procedures.

Colonic DH was defined as follows:

1) Definite Colonic DH (n=207)
   (1) Active bleeding observed from a diverticulum and (2) presence of blood clots, erosions, or an exposed vessel near a diverticulum. Either (1) or (2), absence of blood in the terminal ileum on total CS, and no other obvious cause of bleeding.

2) Suspected Colonic DH (n=66)
   Obvious bloody stools, no blood in the terminal ileum on CS after bowel preparation, and DH as the only likely cause of bleeding.

3. Cases Requiring Blood Transfusion

During hospitalization, patients with significant bleeding or rebleeding and hemoglobin of 7.0 g/dL or ≤8.0 g/dL or patients with hemoglobin of ≥10.0 g/dL in blood sampled on arrival, but in whom hemoglobin decreased by 5.0 g/dL or more from baseline and hemoglobin of <10 g/dL in blood
sampled after several days in hospital because of significant bleeding or rebleeding.

4. Statistical Analysis

All statistical analyses were conducted using the Statistical Analysis System package (SAS Institute, Cary, NC, USA). The chi-square test was used to compare categorical variables between the severe and non-severe DH cases. Unconditional logistic regression was used to compute ORs and their 95% CIs for severe DH. We used age, sex, and other risk factors for severe DH to estimate fully adjusted ORs in relation to factors in the table. Values of $P<0.05$ were considered to be statistically significant.

RESULTS

The number of patients with DH was increased in association with an increase in the number of cases of severe DH (Fig. 1). Table 1 shows the characteristics of patients with severe and non-severe DH. Among the 273 patients with DH, 62 (22.7%) met the criteria for severe DH (transfusion: 56 [20.5%]; rebleeding during hospitalization: 11 [4.0%]; vascular embolization: 2 [0.7%]; surgical treatment: 1 [0.3%]; death: 0 [0%]). Regarding transfusion, 43 patients had significant bleeding or rebleeding with hemoglobin of 7.0 g/dL or ≤8.0 g/dL during hospitalization, while 13 patients had hemoglobin of ≥10.0 g/dL in blood sampled on arrival, but their hemoglobin decreased by 5.0 g/dL or more from baseline and hemoglobin of <10 g/dL in blood sampled after several days in hospital because of significant bleeding or rebleeding. In addition, 204 patients (74.7%) showed spontaneous resolution of bleeding without treatment.

In recent years, bilateral colonic diverticular-type DH has been identified as the most common type (Fig. 2). Frequencies of age ≥70 years ($P=0.04$), BMI ≤18.5 kg/m$^2$ ($P<0.01$), use of ATDs ($P=0.02$), use of NSAIDs ($P<0.01$), CRI ≥2 ($P<0.01$), and right-sided colonic DH ($P<0.01$) were significantly higher among patients with severe DH compared to those with non-severe DH (Table 1). A higher proportion of severe cases was seen among patients with DH from the right colon, compared to other sites (Fig. 3). In addition, symptoms associated with DH ($P=0.02$) and symptoms of cerebral hypoperfusion ($P<0.01$) were more frequent in patients with severe DH than in those with non-severe DH.

We calculated crude ORs (95% CI) and age- and sex-adjusted ORs (95% CI) to evaluate risk factors for the development of severe DH among patients with DH. Table 2 shows age- and sex-adjusted ORs (95% CI) and fully adjusted ORs (95% CI) from multivariate analysis after adjustment for sex, age, thin build (BMI <18.5 kg/m$^2$), ATDs, NSAIDs, CRI ≥2, right-sided colonic DH, and symptoms of cerebral hypoperfusion. Even after controlling for sex, age, and all factors described in the table, oral NSAIDs (OR, 2.801; 95% CI, 1.164–6.742; $P=0.02$), CRI ≥2 (OR, 3.336; 95% CI, 1.154–7.353; $P<0.01$), right-sided colonic DH (OR, 3.873; 95% CI, 1.554–9.653; $P<0.01$), and symptoms of cerebral hypoperfusion (OR, 2.926; 95% CI, 1.310–6.535; $P<0.01$) remained as risk factors for severe DH, while thin build (BMI <18.5 kg/m$^2$) and use of ATDs did not.

DISCUSSION

Colonic DH has recently been reported as the most common cause of LGIB in Japan.\textsuperscript{2,6,9,10} We previously reported that the incidence of DH has increased since 2000.\textsuperscript{1} The present study demonstrated that the number of severe DH patients increased in accordance with the absolute increase in the total number of DH patients.

Bleeding only occurs in 2% to 5% of patients during the natural history of diverticulosis, and most cases are relatively mild, resolving spontaneously in ≥75%–93% of cases.\textsuperscript{11-13} However, rebleeding has been reported in 13% to 38% of cases where bleeding does occur.\textsuperscript{6,8,13-15} Previous case-control studies in Japan identified several risk factors for DH: the use of ATDs and NSAIDs, hypertension, arteriosclerotic diseases such as ischemic heart disease,
### Table 1. Comparison of Patient Characteristics between Severe and Non-severe DH

| Characteristics | Total (n=273) | Severe (n=62) | Non-severe (n=211) | P-value<sup>a</sup> |
|-----------------|--------------|---------------|--------------------|--------------------|
| **Sex**         |              |               |                    |                    |
| Male            | 172 (63.0)   | 35 (56.4)     | 137 (64.9)         | 0.23               |
| Female          | 101 (37.0)   | 27 (43.6)     | 74 (35.1)          |                    |
| **Age**         |              |               |                    |                    |
| ≥70 yr          | 136 (49.8)   | 38 (61.3)     | 98 (46.5)          | 0.04               |
| **BMI (kg/m<sup>2</sup>)** |      |               |                    |                    |
| <18.5           | 27 (9.9)     | 12 (19.4)     | 15 (7.1)           | 0.07               |
| 18.5 to <25     | 151 (55.3)   | 30 (48.4)     | 121 (57.3)         |                    |
| ≥25             | 82 (30.0)    | 17 (27.4)     | 65 (30.8)          |                    |
| Unknown         | 13 (4.8)     | 3 (4.8)       | 10 (4.8)           |                    |
| **Thin BMI <18.5 kg/m<sup>2</sup>** | 27 (9.9) | 12 (20.3) | 15 (7.5) | <0.01 |
| **Oral drugs**  |              |               |                    |                    |
| Use of ATDs     |              |               |                    |                    |
| Yes             | 79 (28.9)    | 25 (40.3)     | 54 (25.6)          | 0.02               |
| 1               | 68 (24.9)    | 22 (35.5)     | 46 (21.8)          | 0.08               |
| ≥2              | 11 (4.0)     | 3 (4.8)       | 8 (3.8)            |                    |
| No              | 193 (70.7)   | 37 (59.7)     | 156 (73.9)         |                    |
| Unknown         | 1 (0.4)      | 0             | 1 (0.5)            |                    |
| Use of NSAIDs   |              |               |                    |                    |
| Yes             | 30 (11.0)    | 13 (21.0)     | 17 (8.1)           | 0.02               |
| No              | 242 (88.6)   | 49 (79.0)     | 193 (91.5)         |                    |
| Unknown         | 1 (0.4)      | 0             | 1 (0.5)            |                    |
| **Lifestyle habits** |        |               |                    |                    |
| Smoking (current and past) | 124 (45.4) | 31 (50.0) | 93 (44.1) | 0.41 |
| Alcohol (current drinking) | 139 (50.9) | 26 (41.9) | 113 (53.6) | 0.11 |
| **History of laparotomy** | | | | |
| Yes             | 59 (21.6)    | 14 (22.6)     | 45 (21.3)          | 0.83               |
| **Underlying disease** |      |               |                    |                    |
| Cerebrovascular disease | 36 (13.2) | 11 (17.7) | 25 (11.9) | 0.23 |
| Ischemic heart disease | 34 (12.5) | 10 (16.1) | 24 (11.4) | 0.32 |
| Hypertension    | 178 (65.2)   | 42 (67.7)     | 136 (64.5)         | 0.63               |
| Hyperlipidemia  | 74 (27.1)    | 14 (22.6)     | 60 (28.4)          | 0.36               |
| Hyperuricemia   | 20 (7.3)     | 6 (9.7)       | 14 (6.6)           | 0.42               |
| Diabetes        | 44 (16.1)    | 11 (17.7)     | 33 (15.6)          | 0.69               |
| Chronic liver disease | 13 (4.8) | 5 (8.1) | 8 (3.8) | 0.17 |
| Chronic kidney disease | 8 (2.9) | 4 (6.5) | 4 (1.9) | 0.06 |
| **Charlson Risk Index** | | | | |
| ≥2              | 79 (28.9)    | 31 (50.0)     | 48 (22.8)          | <0.01              |
| **Site of colonic divertica** | | | | |
| Right-sided     | 87 (31.9)    | 21 (33.9)     | 66 (31.3)          | 0.95               |
| Left-sided      | 48 (17.6)    | 8 (12.9)      | 40 (19.0)          |                    |
| Bilateral       | 138 (50.5)   | 33 (53.2)     | 105 (49.8)         |                    |
| **Site of DH**  |              |               |                    |                    |
| Right-sided     | 116 (42.5)   | 36 (58.1)     | 80 (37.9)          | <0.01              |
| Left-sided      | 91 (33.3)    | 16 (25.8)     | 75 (35.6)          |                    |
| Unknown         | 66 (24.2)    | 10 (16.1)     | 56 (26.5)          |                    |
| **Associated symptoms** | | | | |
| Yes             | 97 (35.5)    | 30 (48.4)     | 67 (31.8)          | 0.02               |
| Abdominal pain  | 36 (13.2)    | 5 (8.1)       | 31 (14.7)          | 0.18               |
| Diarrhea        | 36 (13.2)    | 10 (16.1)     | 26 (12.3)          | 0.44               |
| Cerebral hypoperfusion<sup>b</sup> | 39 (14.3) | 18 (29.0) | 21 (10.0) | <0.01 |

Values are presented as number (%).

<sup>a</sup>Chi-square test.

<sup>b</sup>Light-headedness or dizziness or syncope.

DH, diverticular hemorrhage; ATDs, antithrombotic drugs.
diabetes mellitus, and chronic kidney disease, age ≥70 years, and cluster-type diverticulosis. Other reports confirmed these as risk factors.\(^{1,6,9-11,16,17}\)

Nagata et al.\(^{14}\) reported gradually increasing rates of long-term rebleeding of 3.1%, 19%, 27%, and 38% after 1, 6, 12, and 24 months of follow-up for colonic diverticulosis, respectively, and also reported continued use of oral NSAIDs as a risk factor for rebleeding. Other studies have also reported a 3- to 6-fold increase in the risk of rebleeding in colonic diverticulosis patients taking NSAIDs.\(^{10,15}\) While many reports have examined risks for DH, factors that increase DH severity have seldom been investigated.

Our study aimed to establish severity criteria for DH. We then extracted risk factors for severe DH with an aim to identify and classify these risk factors so that severe DH can be predicted and standardized methods of treatment developed. After comparing patients with severe and non-severe DH, we identified 4 risk factors for increased severity: the use of oral NSAIDs; CRI ≥2; right-sided colonic DH; and symptoms of cerebral hypoperfusion. Besides being a risk factor for both DH and rebleeding, the use of NSAIDs also appears to be a risk factor for severe DH. The mechanisms underlying DH have yet to be fully elucidated. However, colonic diverticula develop at sites where the vasa recta penetrate the large intestinal wall when intestinal pressure increases. Blood vessels in the diverticula are separated from the bowel lumen only by the mucosa and are easily injured. With repeated mechanical stimuli, intimal thickening of the vasa recta occurs, often with thinning of the media. These changes can cause segmental weakening of the vasa recta, which may lead to arterial hemorrhage in the bowel lumen.\(^{18}\)

Arteriosclerosis also plays a role in the pathogenesis, leading to rupture of blood vessels in diverticula.\(^{19,20}\) Blood vessel fragility due to arteriosclerosis may result in bleeding. Patients with colonic diverticulosis and patients who develop DH are generally elderly.\(^{21}\) Moreover, the frequency of arteriosclerosis increases with aging, so the possibility of a pathogenic role of arteriosclerosis in DH warrants consideration. However, not all patients with diverticulosis experience bleeding indeed, most remain asymptomatic. Therefore, in addition to arteriosclerosis, other factors increase the fragility of blood vessels in diverticula.

Multivariate analysis in the present study was performed with adjustment for factors including sex and age, so analysis was performed independently of arteriosclerosis. The results identified NSAIDs as a significant risk factor, suggesting that NSAIDs have a synergistic effect on the injury of blood vessels in diverticula. Most NSAIDs inhibit PG synthesis, which disrupts the microcirculation and inhibits platelet aggregation. Thus, in patients with diverticulosis, NSAIDs can lead to bleeding, including severe DH.\(^{17}\) On the other hand, our study did not find an association between ATDs and severe DH. This suggests a weaker adverse effect of ATDs on DH severity compared with NSAIDs.

The potential reasons for right-sided colonic DH representing a risk factor for severe DH factor must be considered. Right-sided diverticula are often larger than left-sided diverticula, so the vasa recta are more easily injured. In addition, because of the relatively thinner intestinal wall, the amount of bleeding from right-sided colonic diverticulosis is often greater, and the rate of rebleeding is also higher.\(^{19,22}\) Further-
more, because of the longer distance from the anus, bleeding from right-sided colonic diverticulosis is often detected later than bleeding from left-sided colonic diverticulosis, thus increasing DH severity. NSAID-induced colopathy is also reported to occur more commonly in the terminal ileum and right colon. Due to increasing awareness of the upper gastrointestinal (GI) side effects of NSAIDs, enteric-coated and slow-release formulations have been introduced.\(^{23}\) With such formulations, intestinal mucosa in the lower GI tract is directly subjected to free NSAIDs. The fact that the lesions have only been described in the right colon, where the cecum acts as a reservoir and the mucosa is thus subjected to the NSAIDs for a longer time, may support this hypothesis.\(^ {24-26}\) Consequently, use of NSAIDs and bleeding from right-sided colonic diverticula are thought to be strongly associated with severity of DH.

About 50% of patients with colonic DH in our study were ≥70 years old and had a high CRI, which correlates strongly with arteriosclerotic diseases; this was a risk factor for increased DH severity. Although no individual underlying disease alone was identified as a risk factor for severe DH, the CRI assigns scores to conditions including multiple arteriosclerotic diseases. Moreover, the same disease, depending on severity, may yield different scores. The CRI is therefore

---

**Table 2. Multivariate Analysis of Risk Factors for Severe DH among Patients with DH**

| Factor                        | Severe (n=62) | Non-severe (n=211) | Age- and sex-adjusted OR (95% CI) | Fully adjusted OR (95% CI) |
|-------------------------------|---------------|--------------------|-----------------------------------|---------------------------|
| **Sex**                       |               |                    |                                   |                           |
| Male                          | 35 (56.4)     | 137 (64.9)         | 1.000 (reference)                 |                           |
| Female                        | 27 (43.6)     | 74 (35.1)          | 0.798 (0.440–1.446)               |                           |
| **Age (yr)**                  |               |                    |                                   |                           |
| <70                           | 24 (38.7)     | 113 (53.5)         | 1.000 (reference)                 |                           |
| ≥70                           | 38 (61.3)     | 98 (46.5)          | 1.195 (0.578–2.469)               |                           |
| **Thin build**                |               |                    |                                   |                           |
| BMI ≥18.5 kg/m\(^2\)         | 50 (79.7)     | 196 (92.5)         | 1.000 (reference)                 | 1.000 (reference)         |
| BMI <18.5 kg/m\(^2\)         | 12 (20.3)     | 15 (7.5)           | 2.850 (1.227–6.623)\(^{a}\)       | 1.622 (0.597–4.410)       |
| **ATDs**                      |               |                    |                                   |                           |
| No                            | 37 (59.7)     | 157 (74.4)         | 1.000 (reference)                 | 1.000 (reference)         |
| Yes                           | 25 (40.3)     | 54 (25.6)          | 1.867 (0.998–3.492)\(^{b}\)       | 1.252 (0.595–2.635)       |
| **NSAIDs**                    |               |                    |                                   |                           |
| No                            | 49 (79.0)     | 194 (91.9)         | 1.000 (reference)                 | 1.000 (reference)         |
| Yes                           | 13 (21.0)     | 17 (8.1)           | 2.907 (1.310–6.449)\(^{c}\)       | 2.801 (1.164–6.742)\(^{b}\) |
| **CRI**                       |               |                    |                                   |                           |
| ≤1                            | 31 (50.0)     | 163 (77.2)         | 1.000 (reference)                 | 1.000 (reference)         |
| ≥2                            | 31 (50.0)     | 48 (22.8)          | 3.401 (1.787–6.472)\(^{c}\)       | 3.336 (1.154–7.353)\(^{c}\) |
| **Right-sided colonic DH**    |               |                    |                                   |                           |
| No                            | 26 (41.9)     | 131 (62.1)         | 1.000 (reference)                 | 1.000 (reference)         |
| Yes                           | 36 (58.1)     | 80 (37.9)          | 3.157 (1.662–5.996)\(^{a}\)       | 3.873 (1.554–9.653)\(^{c}\) |
| **Cerebral hypoperfusion**\(^{d}\) |           |                    |                                   |                           |
| No                            | 44 (71.0)     | 190 (90.0)         | 1.000 (reference)                 | 1.000 (reference)         |
| Yes                           | 18 (29.0)     | 21 (10.0)          | 3.637 (1.771–7.469)\(^{c}\)       | 2.926 (1.310–6.535)\(^{f}\) |

Values are presented as number (%).

\(^{a}\)OR adjusted for age, sex and all factors in the table.

\(^{b}\)\(P<0.05\).

\(^{c}\)\(P<0.01\).

\(^{d}\)Light-headedness or dizziness or syncope.

DH, diverticular hemorrhage; ATDs, antithrombotic drugs; CRI, Charlson Risk Index.
thought to offer a useful index of arteriosclerosis severity and multiple comorbid conditions.

In addition, our study identified symptoms of cerebral hypoperfusion (light-headedness or dizziness or syncope) as a risk factor for DH severity. Lee et al.27 also included a systolic blood pressure (SBP) of ≤90 mmHg as a criterion for severe DH. This can signify an acute fall in blood pressure due to massive bleeding. In our study, symptoms of cerebral hypoperfusion such as light-headedness, dizziness, and syncope suggested acute massive bleeding, necessitating urgent treatment, including blood transfusions. Endoscopic treatment, which may avoid the need for emergency surgery and prevent further bleeding,28 should be instituted aggressively for patients in a stable general condition. In this study, as shown in Table 3, only 10 patients had a SBP of ≤90 mmHg. Moreover, since patients in shock or with unstable vital signs could not undergo endoscopic examination, they were not included in the study. However, the relationship between the severity of DH and SBP ≤90 mmHg had a low sensitivity of 12.9%, and was thus omitted from the investigation items in the analysis despite its high specificity (99.1%).

Nagata et al.29 described female sex, warfarin, chronic kidney disease, age ≥70 years, and NSAID use as risk factors for severity in DH (defined based on the need for transfusion and long-term hospitalization). Aoki et al.30 presented 8 factors (CRI ≥2, syncope, absence of diarrhea, absence of abdominal tenderness, use of NSAIDs, use of non-aspirin antiplatelet drugs, blood pressure ≤100 mmHg, and albumin <3.0 g/dL) as risk factors for severity in LGIB including colonic DH (continued bleeding during the first 24 hours [transfusion of ≥2 units of packed red blood cells and/or decrease in hematocrit of ≥20%], and/or recurrent bleeding after initial CS [rectal bleeding accompanied by further decrease in hematocrit of ≥20% and/or additional blood transfusions]). Both studies29,30 showed points in common with the present study.

Table 3. Severe DH among Patients with DH versus SBP

| DH | Severe (n=62) | Non-severe (n=211) |
|----|--------------|-------------------|
| SBP ≤90 mmHg (n=10) | 8 | 2 |
| SBP >90 mmHg (n=263) | 54 | 209 |

DH: diverticular hemorrhage; SBP: systolic blood pressure. Sensitivity: 12.9%; specificity: 99.1%; positive predictive value: 80.0%; negative predictive value: 79.5%.

Our study examined DH patients who underwent CS for LGIB over a 19-year period, including detailed information about underlying diseases and medications. The investigation included a relatively large cohort of 273 patients with colonic DH for comparison and analysis. We also compared the baseline data of patients with severe and non-severe DH patients among all subjects in this cohort. We were able to understand the changes with time and incidence over a long period in patients with severe DH.

There are some limitations to our study. One was the retrospective nature of the study design, and another was the fact that only a single institution was involved. In addition, multi-detector row CT was not used at the initial visit to evaluate the site of bleeding, so accurate determinations could not be made in all cases. Furthermore, this study included ex-smokers as smokers. However, a patient who has not smoked for more than 10 years may not have the same risk as a current smoker. However, we were unable to collect more detailed information about smoking habits, due to the retrospective nature of the study. We also did not evaluate general arteriosclerosis via carotid artery ultrasonography. We checked charts and reviewed the patients’ heart rate at the time of initial visit. But details of the heart rate were not described in more than 40 cases out of 273 cases. Therefore, this item was not able to be added as risk factor in this study.

The strengths of this study are 2-fold: Firstly, there was no selection bias because we selected all severe and all non-severe patients among the DH patients in our retrospective cohort. Secondly, there was little information bias in this study because we used information from medical records before and at the diagnosis of DH.

In conclusion, patients with multiple arteriosclerosis-related diseases and/or those taking NSAIDs were more likely to have severe DH, including a higher risk of rebleeding and a need for blood transfusions. Measures to prevent rebleeding such as stopping NSAIDs may be necessary in these patients. Patients showing symptoms of cerebral hypoperfusion or bleeding from right-sided diverticulosis are also at risk of severe DH. These patients require urgent treatment, including endoscopy to identify the source of bleeding. These factors thus should be kept in mind when treating patients with DH.

FINANCIAL SUPPORT

The authors received no financial support for the research, authorship, and/or publication of this article.

CONFLICT OF INTEREST

No potential conflict of interest relevant to this article was reported.
AUTHOR CONTRIBUTION

Kinjo K collected and analyzed the data, and drafted the manuscript; Matsui T designed and supervised the study; Washio M performed the statistical analysis; Hisabe T, Ishihara H, Kojima T, Chuman K, Yasukawa S, Beppu T, Koga A, Ishikawa S, Kishi M, Takatsu N, Hirai F, Yao K, Ueki T performed the colonoscopy and revised the manuscript for important intellectual content; all authors have read and approved the final version to be published.

ACKNOWLEDGEMENTS

We wish to thank Mr. Matt Morgan of Forte, Inc. for providing advice on the use of English in the manuscript.

REFERENCES

1. Kinjo K, Matsui T, Hisabe T, et al. Increase in colonic diverticular hemorrhage and confounding factors. World J Gastrointest Pharmacol Ther 2016;7:440-446.
2. Nagata N, Niikura R, Aoki T, et al. Lower GI bleeding risk of nonsteroidal anti-inflammatory drugs and antiplatelet drug use alone and the effect of combined therapy. Gastrointest Endosc 2014;80:1124-1131.
3. Hreinsson JP, Gumundsson S, Kalaitzakis E, Björnsson ES. Lower gastrointestinal bleeding: incidence, etiology, and outcomes in a population-based setting. Eur J Gastroenterol Hepatol 2013;25:37-43.
4. Lanas A, García-Rodríguez LA, Polo-Tomás M, et al. Time trends and impact of upper and lower gastrointestinal bleeding and perforation in clinical practice. Am J Gastroenterol 2009;104:1633-1641.
5. Stollman N, Raskin JB. Diverticular disease of the colon. Lancet 2004;363:631-639.
6. Tsuruoka N, Iwakiri R, Hara M, et al. NSAIDs are a significant risk factor for colonic diverticular hemorrhage in elder patients: evaluation by a case-control study. J Gastroenterol Hepatol 2011;26:1047-1052.
7. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-383.
8. Jensen DM, Machicado GA, Jutabha R, Kovacs TO. Urgent colonoscopy for the diagnosis and treatment of severe diverticular hemorrhage. N Engl J Med 2000;342:78-82.
9. Yamada A, Sugimoto T, Kondo S, et al. Assessment of the risk factors for colonic diverticular hemorrhage. Dis Colon Rectum 2008;51:116-120.
10. Okamoto T, Watabe H, Yamada A, Hirata Y, Yoshida H, Koike K. The association between arteriosclerosis related diseases and diverticular bleeding. Int J Colorectal Dis 2012;27:1161-1166.
11. Niikura R, Nagata N, Shimbo T, et al. Natural history of bleeding risk in colonic diverticulosis patients: a long-term colonoscopy-based cohort study. Aliment Pharmacol Ther 2015;41:888-894.
12. McGuire HH Jr. Bleeding colonic diverticula: a reappraisal of natural history and management. Ann Surg 1994;220:653-656.
13. Puncet G, Heluwaert F, Voirin D, Bonaz B, Faucheron JL. Natural history of acute colonic diverticular bleeding: a prospective study in 133 consecutive patients. Aliment Pharmacol Ther 2010;32:466-471.
14. Nagata N, Niikura R, Aoki T, et al. Impact of discontinuing non-steroidal antiinflammatory drugs on long-term recurrence in colonic diverticulic bleeding. World J Gastroenterol 2015;21:1292-1298.
15. Niikura R, Nagata N, Yamada A, Akiyama J, Shimbo T, Uemura N. Recurrence of colonic diverticular bleeding and associated risk factors. Colorectal Dis 2012;14:302-305.
16. Niikura R, Nagata N, Akiyama J, Shimbo T, Uemura N. Hypertension and comorbid arteriosclerotic diseases are risk factors for colonic diverticular bleeding: a case-control study. Int J Colorectal Dis 2012;27:1137-1143.
17. Aldoori WH, Giovannucci EL, Rimm EB, Wing AL, Willett WC. Use of acetaminophen and nonsteroidal anti-inflammatory drugs: a prospective study and the risk of symptomatic diverticular disease in men. Arch Fam Med 1998;7:255-260.
18. Meyers MA, Alonso DR, Baer JW. Pathogenesis of massively bleeding colonic diverticulosis: new observations. AJR Am J Roentgenol 1976;127:901-908.
19. Hussain A, Mahmood H, Subhas G, El-Hasani S. Complicated diverticular disease of the colon, do we need to change the classical approach, a retrospective study of 110 patients in south east England. World J Emerg Surg 2008;3:5.
20. Chen CY, Wu CC, Jao SW, Pai L, Hsiao CW. Colonic diverticular bleeding with comorbid diseases may need elective colectomy. J Gastrointest Surg 2009;13:516-520.
21. Nagata N, Niikura R, Aoki T, et al. Increase in colonic diverticulosis and diverticular hemorrhage in an aging society: lessons from a 9-year colonoscopic study of 28,192 patients in Japan. Int J Colorectal Dis 2014;29:379-385.
22. Wong SK, Ho YH, Leong AP, Seow-Cohen F. Clinical behavior of complicated right-sided and left-sided diverticulosis. Dis Colon Rectum 1997;40:344-348.
23. García Rodríguez LA, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769-772.
24. Geramizadeh B, Taghavi A, Banan B. Clinical, endoscopic and pathologic spectrum of non-steroidal anti-inflammatory drug-induced colitis. Indian J Gastroenterol 2009;28:150-153.

25. Masannat YA, Harron M, Harinath G. Nonsteroidal anti-inflammatory drugs-associated colopathy. ANZ J Surg 2010;80:96-99.

26. Halter F, Weber B, Huber T, Eigenmann F, Frey MP, Ruchti C. Diaphragm disease of the ascending colon. Association with sustained-release diclofenac. J Clin Gastroenterol 1993;16:74-80.

27. Lee KK, Shah SM, Moser MA. Risk factors predictive of severe diverticular hemorrhage. Int J Surg 2011;9:83-85.

28. Pilichos C, Bobotis E. Role of endoscopy in the management of acute diverticular bleeding. World J Gastroenterol 2008;14:1981-1983.

29. Nagata N, Niikura R, Aoki T, et al. Risk factors for adverse in-hospital outcomes in acute colonic diverticular hemorrhage. World J Gastroenterol 2015;21:10697-10703.

30. Aoki T, Nagata N, Shimbo T, et al. Development and validation of a risk scoring system for severe acute lower gastrointestinal bleeding. Clin Gastroenterol Hepatol 2016;14:1562-1570.e2.